Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Monday, down -12.45% from the previous trading day, before settling in for the closing price of $5.22. Over the past 52 weeks, VERV has traded in a range of $4.30-$13.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 136.15% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -13.49%. With a float of $66.18 million, this company’s outstanding shares have now reached $88.76 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 84.37%, operating margin of -707.23%, and the pretax margin is -613.51%.
Verve Therapeutics Inc (VERV) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 25.47%, while institutional ownership is 69.92%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.30% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 12.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.35, a number that is poised to hit -0.65 in the next quarter and is forecasted to reach -2.69 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was inferior than the volume of 1.44 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.46%. Additionally, its Average True Range was 0.52.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 2.67%, which indicates a significant increase from 1.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.76% in the past 14 days, which was lower than the 100.25% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.86, while its 200-day Moving Average is $5.99. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $4.88. Second resistance stands at $5.19. The third major resistance level sits at $5.36. If the price goes on to break the first support level at $4.40, it is likely to go to the next support level at $4.23. Assuming the price breaks the second support level, the third support level stands at $3.92.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 405.80 million has total of 88,796K Shares Outstanding. Its annual sales at the moment are 32,330 K in contrast with the sum of -198,710 K annual income. Company’s last quarter sales were recorded 13,080 K and last quarter income was -50,040 K.
